Filling the gap between science & clinical practice: Prevention of stroke recurrence

Thrombosis Research

Volumn 129, Issue 1, 2012, Pages 3-8

  Russolillo, Anna ^a   Di Minno, Matteo Nicola Dario ^a   Tufano, Antonella ^a   Prisco, Domenico ^b   Di Minno, Giovanni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Active secondary prevention; Clinical practice; Gaps; Recommendations; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIVITAMIN K; ATORVASTATIN; CLOPIDOGREL; DABIGATRAN ETEXILATE; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RIVAROXABAN; TICLOPIDINE; WARFARIN;

ATHEROTHROMBOTIC STROKE; BLEEDING; BRAIN HEMORRHAGE; CARDIOEMBOLIC STROKE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; STROKE; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ATTITUDE OF HEALTH PERSONNEL; CARDIOVASCULAR AGENTS; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME;

EID: 84655163437     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.08.012     Document Type: Review

References (50)

1. J.D. Marsh, and S.G. Keyrouz Stroke Prevention and Treatment J Am Coll Cardiol 56 2010 683 691
2. C. Warlow, C. Suldow, M. Dennis, J. Wardlaw, and P. Sandercock Stroke Lancet 362 2003 1211 1224 (Pubitemid 37255350)
3. G.W. Albers, P. Amarenco, J.D. Easton, R.L. Sacco, and P. Teal Antithrombotic and Thrombolytic therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic therapy Chest 126 2004 483S 512S (Pubitemid 39297962)
4. Ictus cerebrale: linee guida italiane di prevenzione e trattamento www.spread.it
5. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an indipendent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
6. D.E. Singer, G.W. Albers, J.E. Dalen, M.C. Fang, A.S. Go, and J.L. Halperin Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 546S 592S (Pubitemid 351892972)
7. B.F. Gage, C. van Walraven, L. Pearce, R.G. Hart, P.J. Koudstaal, and B.S. Boode Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin Circulation. 110 2004 Oct 19 2287 2292 (Pubitemid 39407328)
8. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Guidelines for the management of atrial fibrillation Eur Heart J 31 2010 2369 2429
9. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation Chest 137 2010 263 272
10. M. Marcucci, A. Iorio, A. Nobili, M. Tettamanti, L. Pasina, and A. Marengoni Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards Eur J Intern Med 21 2010 516 523
11. M.S. Dhamoon, R.R. Sciacca, T. Rundek, R.L. Sacco, and M.S. Elkind Recurrent stroke and cardiac risk after first ischemic stroke: the Northen Manhattan Study Neurology 66 2006 641 646 (Pubitemid 43739815)
12. G.J. Hankey Long-term outcome after ischaemic stroke/transient ischaemic attack Cerebrovasc Dis 16 Suppl. 1 2003 14 19 (Pubitemid 36438779)
13. P. Rashid, J. Leonardi-Bee, and P. Bath Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review Stroke 34 2003 2741 2748 (Pubitemid 37392777)
14. The European Stroke Organization (ESO) Executive Committee The ESO Writing Committee Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008
15. R.J. Adams, G. Albers, and M.J. Alberts Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack Stroke 39 2008 1647 1652
16. C. Weimar, H.C. Diener, M.J. Alberts, P.G. Steg, D.L. Bhatt, and P.W. Wilson The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry Stroke 40 2009 350 354
17. M. Paciaroni, and J. Bogousslavsky Statins and stroke prevention Expert Rev Cardiovasc Ther 7 2009 1231 1243
18. P. Amarenco, J. Bogousslavsky, A. Callahan, and L. Goldtein High-dose atorvastatin after stroke or transient ischaemic attack N Engl J Med 355 2006 549 559 (Pubitemid 44202151)
19. D.L. Bhatt, P.G. Steg, and E.M. Ohman International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis JAMA 295 2006 180 189 (Pubitemid 43076437)
20. Executive Summary of the Third Report of the National Cholesterol education Program (NCEP) export Panel of Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
21. M.J. Alberts, D.L. Bhatt, J.L. Mas, and E.M. Ohman Three-Year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry Eur Heart J 30 2009 2318 2326
22. V. Toso, A. Carolei, G.F. Gensini, and C. Cimminiello The stroke in Italy and related impact on outcome (SIRIO) study: design and baseline data Neurol Sci 27 2006 S263 S267
23. A. Filippi, E. Tragni, and A.A. Bignamini Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice Eur J Cardiovasc Prev Rehabil 12 2005 159 163 (Pubitemid 40571529)
24. A. Filippi, A.A. Bignamini, O. Brignoli, and E. Sessa Secondary prevention of stroke in Italy: a cross-sectional survey in family practice Stroke 34 2003 1010 1014 (Pubitemid 36402980)
25. A. Filippi, G.F. Gensini, and A.A. Bignamini Management of patients with suspected angina, but without known myocardial infarction: a cross-sectional survey Br J Gen Pract 54 2004 429 433 (Pubitemid 38771888)
26. T. Leoo, A. Lindgren, J. Petersson, and M. von Arbin Risk Factors and Treatment at Recurrent Stroke Onset: Results from the Recurrent Stroke Quality and Epidemiology (RESQUE) Study Cerebrovasc Dis 25 2008 254 260 (Pubitemid 351450429)
27. G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation Ann Intern Med 146 2007 857 867 (Pubitemid 351650486)
28. J. Mant, R. Hobbs, and K. Fletcher Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial Lancet 370 2007 493 503 (Pubitemid 47212371)
29. L. Brass, L. Krumholz, and J. Scinto Warfarin use following ischemic stroke among medicare patients with atrial fibrillation Arch Intern Med 158 1998 2093 2100 (Pubitemid 28482091)
30. C. Lafuente, I. Mahe, and F. Extramiana Management of atrial fibrillation BMJ 339 2009 b5216
31. Stroke Preventionin Atrial Fibrillation Adjusted-dose warfarin versus low-intensity fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial Lancet 348 1996 633 638
32. A.L. Gulløv, B.G. Koefoed, P. Petersen, T.S. Pedersen, E.D. Andersen, and J. Godtfredsen Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study Arch Intern Med 158 1998 1513 1521 (Pubitemid 28340984)
33. P. Lechat, H. Lardoux, A. Mallet, P. Sanchez, G. Derumeaux, and T. Lecompte Anticoagulant (fluindione)-aspirin combination in patients with highrisk atrial fibrillation: a randomized trial Cerebrovasc Dis 12 2001 245 252
34. F. Perez-Gomez, E. Alegria, J. Berjon, J.A. Iriarte, J. Zumalde, and A. Salvador Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and non-valvular atrial fibrillation: a randomized multicenter study J Am Coll Cardiol 44 2004 1557 1566 (Pubitemid 39377708)
35. M.C. Vedovati, C. Becattini, and G. Agnelli Combined oral anticoagulants and antiplatelets: benefits and risks Intern Emerg Med 5 2010 281 290
36. ACTIVE Investigators, S.J. Connolly, J. Pogue, R.G. Hart, S.H. Hohnloser, and M. Pfeffer Effect of clopidogrel added to aspirin in patients with atrial fibrillation N Engl J Med 360 2009 2066 2078
37. ACTIVE Writing Group of the ACTIVE Investigators, S. Connolly, J. Pogue, R. Hart, M. Pfeffer, and S. Hohnloser Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
38. I. Ben-Dor, N.S. Kleiman, and E. Lev Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy Am J Cardiol 104 2009 227 233
39. J.W. Eikelboom, J. Hirsh, J.I. Weitz, M. Jhonson, Q. Yi, and S. Yusuf Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 105 2002 1650 1655 (Pubitemid 34298607)
40. 2? Circulation 105 2002 1620 1622 (Pubitemid 34298600)
41. F. Sofi, R. Marcucci, and A.M. Gori Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An update meta-analysis Thromb Haemost 103 2010 841 848
42. G. Montalescot, S. Wiviott, and E. Braunwald Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial Lancet 373 2009 723 731
43. P.G. Steg, S. James, and R.A. Harrington Ticagrelor versus Clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet inhibition and Patient Outcomes (PLATO) trial subgroup analysis Circulation 122 2010 2131 2141
44. M.N. Di Minno, A. Russolillo, M. Camera, M. Brambilla, A. De Gregorio, and E. Tremoli New Anti-Thrombotic Drugs for Stroke Prevention Curr Vasc Pharmacol 9 2011 723 732
45. J. Hirsh, J.E. Dalen, D.R. Anderson, L. Poller, H. Bussey, and J. Ansell Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range Chest 114 1998 445S 469S (Pubitemid 28535775)
46. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
47. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, P.A. Reilly, and L. Wallentin Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial N Engl J Med 363 2010 1875 1876
48. The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators Rivaroxaban - Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study Am Heart J 159 2010 340 347 e1
49. E. Romualdi, and W. Ageno Oral Xa inhibitors Hematol Oncol Clin North Am 24 2010 727 737
50. E.D. Peterson, M.T. Roe, J. Mulgund, E.R. DeLong, B.L. Lytle, and R.G. Brindis Association between hospital process performance and outcomes among patients with acute coronary syndromes JAMA 295 2006 1912 1920